Search the Newsreel

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Report - Results, Call & Slides

Alamar Biosciences, Inc. (ALMR) reported its Q2 2026 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of -$0.22 against a consensus of -$0.31, and actual revenue of $29.40 million compared to an expected $25.86 million. The earnings call took …

Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM)

This article summarizes recent analyst ratings for three North American companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ), and Amentum Holdings, Inc. (AMTM). Bank of America Securities reiterated a Hold rating on Alamar Biosciences and a Buy rating on NIQ Global Intelligence, …

Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH

(RTTNews) - The following biotech stocks reached a 52-week high on August 11, 2026, driven up by key catalysts such as positive quarterly or full year reports. Alamar Biosciences Inc. (ALMR) Alamar Biosciences is a proteomics company that has develops a liquid biopsy platform …

Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake

Qiming funds have reported a significant ownership stake in Alamar Biosciences, Inc. (ALMR) through a Schedule 13G filing. Qiming Corporate GP VI, Ltd and related entities collectively hold 10.2% beneficial ownership, translating to 7,066,573 shares based on 69,311,186 shares outstanding as of April 30, …

Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up

Alamar Biosciences (ALMR) shares surged 31% after reporting an 82% increase in second-quarter revenue, primarily driven by a 147% surge in consumable sales. Consumables now account for 52.6% of revenue, boosting gross margin to 60%. Despite continued operating losses, the company's strong revenue growth …

Alamar Biosciences Q2 Results: Revenue Rises 82% To $29.4 Million

Stifel raises Alamar Biosciences stock price target on earnings beat

Stifel has increased its target price for ALAMAR BIOSCIENCES INC to $32 from $28. This update, reported by Reuters, reflects an analyst's revised valuation for the company. The article emphasizes that the content represents the author's opinion and should not be used as investment …

Earnings Flash (ALMR) Alamar Biosciences, Inc. Reports Q2 Revenue $29.4M, Vs. FactSet Est of $25.9M

Alamar Biosciences, Inc. (ALMR) announced its second-quarter revenue of $29.4 million, significantly exceeding the FactSet estimate of $25.9 million. This earnings flash highlights the company's financial performance for the recent quarter.

ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28

Stifel has increased its target price for ALAMAR BIOSCIENCES INC to $32 from $28. This update, reported by Reuters, reflects an analyst's revised valuation for the company. The article emphasizes that the content represents the author's opinion and should not be used as investment …

Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside

Alamar Biosciences, Inc.'s average 12-month price target has been increased from $31.8 to $33.4 by 5 analysts, with forecasts ranging from $31 to $35 per share. This new target implies approximately 19% potential upside based on the August 10 closing price. The consensus rating …

Alamar Biosciences, Inc. 2Q 2026: Revenue $29.4M, EPS $(0.22) — 10-Q Summary

Alamar Biosciences, Inc. reported its second-quarter 2026 results, showing revenue of $29.4 million, an 82% increase year-over-year, driven by a surge in consumables sales. Despite this growth, the company recorded a net loss of $13.2 million and a diluted loss per share of $(0.22). …

Alamar Biosciences (ALMR) Earnings Date and Reports 2026

Alamar outlines $116M-$120M 2026 revenue outlook while targeting 100+ instruments and $400,000+ pull-through

Earnings Call Insights: Alamar Biosciences (ALMR) Q2 2026 MANAGEMENT VIEW * “Q2 2026 was a strong quarter that reflects the momentum of our business,” said Co-Founder, Chairman & CEO Yuling Luo, highlighting that “Total revenue grew 82% year-over-year,” that “Consumable revenue accounted for 53% …

Alamar Biosciences FY26 sales guidance beats estimates

Alamar Biosciences (NASDAQ: ALMR) reported strong Q2 2026 results with an 82% revenue surge to $29.4 million, primarily driven by a 147% increase in consumable sales. The company raised its full-year 2026 revenue guidance to $116-$120 million, surpassing analyst estimates. Despite a widening net …

Alamar Biosciences expands proteomics partnership by 86,000 samples

Alamar Biosciences is expanding its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to analyze an additional 86,000 plasma samples using its NULISAseq Neuro 220 panel. This expansion builds on a previous initiative that profiled over 55,000 samples, aiming for a total …

Alamar: Q2 Earnings Snapshot

Alamar Biosciences Inc. (ALMR) reported a Q2 loss of $13.2 million, or 22 cents per share, which surpassed Wall Street expectations of a 36-cent loss. The biotech company, specializing in proteomics, posted revenue of $29.4 million for the period and projects full-year revenue between …

Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance

Alamar Biosciences reported strong second-quarter 2026 financial results, with total revenue increasing by 82% to $29.4 million and consumable revenue growing by nearly 150% year-over-year. The company also launched new products, including a multiplexed immunoassay for eMTBR-tau and the NULISAseq™ Immune 340 Panel, and …

Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures

Alamar Biosciences has expanded its partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures to profile an additional 86,000 plasma samples using its NULISAseq™ Neuro 220 panel. This collaboration aims to create the largest neurodegenerative disease dataset, encompassing over 140,000 samples by 2027, …

Alamar Biosciences (ALMR) Introduced Its NULISAseq Immune 340 Panel

Alamar Biosciences Inc expected to post a loss of 33 cents a share - Earnings Preview

Alamar Biosciences Inc is projected to report a loss of 33 cents per share, according to this earnings preview. The article, sourced from Reuters via Refinitiv, provides an outlook on the company's upcoming financial performance.

Alamar Biosciences, Inc. - Class A common stock (Nasdaq:ALMR) Stock Quote

This page provides a stock quote for Alamar Biosciences, Inc. (Nasdaq: ALMR), showing its current trading price, daily performance, and key financial metrics like volume and trading ranges. It also lists recent news, including Q2 2026 earnings, partnership announcements, and new product launches, highlighting …

Alamar Biosciences (Nasdaq:ALMR) - Stock Analysis

This report provides a detailed stock analysis of Alamar Biosciences (ALMR), a proteomics company focusing on early disease detection. It covers the company's financial health, future growth prospects, recent news, and market performance. Key highlights include the launch of new NULISAseq panels for immune …

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

Alamar Biosciences has launched the NULISAseq™ Immune 340 Panel, an expanded multiplexed immune profiling solution designed for translational research and drug development. This panel allows for the simultaneous measurement of approximately 340 immune-related proteins, including those previously undetectable by other methods, to deepen understanding …